Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Testosterone Enanthate

FDA-approved product (injectable, injection), marketed as Delatestryl, Testosterone Enanthate, Xyosted (Autoinjector).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Enanthate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Testosterone Enanthate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Enanthate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

    NCT07742553 · start 2027-10-01

    Registered record
    Registry ID
    NCT07742553
    Conditions
    Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord; Spinal Cord Contusion; Spinal Cord Trauma; Trauma, Nervous System; Wounds and Injuries; Spinal Cord Compression; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male
    Interventions
    testosterone cypionate; finasteride; placebo injection; placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-10-01
    Completion
    2032-03-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord; Spinal Cord Contusion +10 more
    Interventiontestosterone cypionate; finasteride; placebo injection; placebo pill
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

    NCT07568574 · start 2026-03-12

    Registered record
    Registry ID
    NCT07568574
    Conditions
    Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    Interventions
    Testosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone); Testosterone Gel; Methenolone Enanthate (Primobolan); Nandrolone Decanoate (Deca-Durabolin); Estradiol Patch; Estradiol Capsule; Progesterone Cream; Progesterone Capsule; Human Growth Hormone (hGH); EPO Darbepoetin (Aranesp); Meldonium; Modafinil; Mixed amphetamine salts (Adderall); Clomiphene; Anastrozole; Levothyroxine; Liothyronine; hCG; hMG; Atorvastatin; Rosuvastatin; Bisoprolol; Nebivolol; Metoprolol; Propranolol; Lisinopril; Enalapril; Furosemide; Chlorothiazide; Cabergoline; Metformin; Basal Insulin Glargine (long-acting); Telmisartan; Losartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-03-12
    Completion
    2033-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    InterventionTestosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone) +33 more
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

    NCT06689085 · start 2025-03-07

    Registered record
    Registry ID
    NCT06689085
    Conditions
    Hypogonadism, Male
    Interventions
    Testosterone enanthate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-07
    Completion
    2030-03
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male
    InterventionTestosterone enanthate
    PhasePhase 3
    Registry statusRecruiting

  • Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

    NCT06393634 · start 2024-11-27

    Registered record
    Registry ID
    NCT06393634
    Conditions
    Healthy
    Interventions
    Testosterone injection; Testosterone gel; Testosterone Oral
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-11-27
    Completion
    2024-11-27
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTestosterone injection; Testosterone gel; Testosterone Oral
    PhaseEarly phase 1
    Registry statusCompleted

  • Working Out M0 Bipolar Androgen Therapy

    NCT06594926 · start 2024-08-14

    Registered record
    Registry ID
    NCT06594926
    Conditions
    Prostate Cancer
    Interventions
    Testosterone Enanthate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-14
    Completion
    2028-12-31
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTestosterone Enanthate
    PhasePhase 2
    Registry statusRecruiting

  • Extracellular Vesicles and Endothelial Function in Transgender Subjects

    NCT04971447 · start 2022-08

    Registered record
    Registry ID
    NCT04971447
    Conditions
    Transgenderism
    Interventions
    gender affirming hormonal treatment in transgender men; gender affirming hormonal treatment in transgender women
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-08
    Completion
    2024-01
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransgenderism
    Interventiongender affirming hormonal treatment in transgender men; gender affirming hormonal treatment in transgender women
    PhaseNot applicable
    Registry statusUnknown

  • Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men

    NCT04593680 · start 2022-01-24

    Registered record
    Registry ID
    NCT04593680
    Conditions
    Drug Interaction
    Interventions
    Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2022-01-24
    Completion
    2025-10-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction
    InterventionEmtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
    PhaseNot applicable
    Registry statusActive not recruiting

  • Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

    NCT03674320 · start 2021-12-01

    Registered record
    Registry ID
    NCT03674320
    Conditions
    COPD
    Interventions
    Testosterone Enanthate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2021-12-01
    Completion
    2024-12-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionTestosterone Enanthate; Placebo
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

    NCT04460872 · start 2021-01-31

    Registered record
    Registry ID
    NCT04460872
    Conditions
    Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injury; Central Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male; Spinal Cord Trauma; Injuries, Spinal Cord; Walking, Difficulty; Gait Disorders, Neurologic; Locomotion Disorder, Neurologic; Wounds and Injuries; Nervous System Diseases; Testosterone Deficiency; Androgen Deficiency; Hormone Deficiency
    Interventions
    Testosterone Enanthate; Locomotor Training
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-01-31
    Completion
    2026-06-30
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injury +16 more
    InterventionTestosterone Enanthate; Locomotor Training
    PhasePhase 2
    Registry statusRecruiting

  • Testosterone Effects on Pelvic Floor Muscles

    NCT04026880 · start 2021-01-01

    Registered record
    Registry ID
    NCT04026880
    Conditions
    Urinary Incontinence; Menopause
    Interventions
    Testosterone Enanthate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2021-01-01
    Completion
    2022-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Incontinence; Menopause
    InterventionTestosterone Enanthate; Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

    NCT04363164 · start 2020-08-19

    Registered record
    Registry ID
    NCT04363164
    Conditions
    Castration Resistant Metastatic Prostate Cancer
    Interventions
    Testosterone cypionate; Enzalutamide; Testosterone enanthate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-08-19
    Completion
    2028-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Resistant Metastatic Prostate Cancer
    InterventionTestosterone cypionate; Enzalutamide; Testosterone enanthate
    PhasePhase 2
    Registry statusRecruiting

  • Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

    NCT03516812 · start 2018-08-29

    Registered record
    Registry ID
    NCT03516812
    Conditions
    Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma
    Interventions
    Laboratory Biomarker Analysis; Olaparib; Quality-of-Life Assessment; Survey Administration; Testosterone Enanthate; Testosterone Cypionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-29
    Completion
    2024-04-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma
    InterventionLaboratory Biomarker Analysis; Olaparib; Quality-of-Life Assessment; Survey Administration +2 more
    PhasePhase 2
    Registry statusCompleted

  • Bipolar Androgen Therapy + Carboplatin in mCRPC

    NCT03522064 · start 2018-07-30

    Registered record
    Registry ID
    NCT03522064
    Conditions
    Castration-resistant Prostate Cancer; Homologous Recombination Deficiency
    Interventions
    Testosterone Enanthate 100 MG/ML Injectable Solution; Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2018-07-30
    Completion
    2027-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-resistant Prostate Cancer; Homologous Recombination Deficiency
    InterventionTestosterone Enanthate 100 MG/ML Injectable Solution; Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
    PhasePhase 2
    Registry statusRecruiting

  • Study of Testosterone and rHGH in FSHD

    NCT03123913 · start 2017-12-18

    Registered record
    Registry ID
    NCT03123913
    Conditions
    Facioscapulohumeral Muscular Dystrophy
    Interventions
    Testosterone Enanthate; Somatropin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-12-18
    Completion
    2022-03-28
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFacioscapulohumeral Muscular Dystrophy
    InterventionTestosterone Enanthate; Somatropin
    PhasePhase 1
    Registry statusCompleted

  • Testosterone Plus Finasteride Treatment After Spinal Cord Injury

    NCT02248701 · start 2017-04-27

    Registered record
    Registry ID
    NCT02248701
    Conditions
    Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries; Central Nervous System Diseases; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male
    Interventions
    Testosterone Enanthate; Finasteride; Placebo injection; Placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-04-27
    Completion
    2021-08-13
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries +7 more
    InterventionTestosterone Enanthate; Finasteride; Placebo injection; Placebo pill
    PhasePhase 2
    Registry statusTerminated